Both the vaccine from the manufacturers BioNTech and Pfizer and the preparation from Moderna could be used for this, the committee unanimously decided on Wednesday after hours of discussion.
The result of the vote is not binding for the FDA, but the authority usually follows the assessment of the consultants. The CDC has yet to agree. This could soon start vaccinations against the corona virus in this age group in the USA. The US government said a few days ago that it was expected from June 21st.
Federal Minister of Health Karl Lauterbach welcomed the US Food and Drug Administration’s recommendation. “This is good news for parents,” wrote the SPD politician on Twitter on Wednesday evening.
BioNTech/Pfizer’s vaccine is currently approved in the United States for children ages five to 11, and Moderna’s vaccine for people ages 18 and older. On Tuesday, however, the FDA advisory committee had already spoken out in favor of approving Moderna’s vaccine for children and adolescents between the ages of 6 and 17.
There is currently no corona vaccine approved for very young children in the EU. The European Medicines Agency EMA in Amsterdam is currently examining whether the vaccine from the manufacturer Moderna (Spikevax) can also be approved for children under the age of six. Such a test has not yet started for the vaccine from the manufacturers BioNTech and Pfizer. According to the EMA, the manufacturers have not yet submitted a corresponding application for an extension of the approval.
BioNTech shares are temporarily down 3.04 percent to $133.80 in trading on the NASDAQ, while Moderna shares are down 3.25 percent to $124.35. Pfizer shares on the NYSE are now down 1.28 percent to $47.89.
WASHINGTON (dpa-AFX)
Leverage must be between 2 and 20
No data
More news about BioNTech (ADRs)
Image sources: Thomas Lohnes/Getty Images, Marco Lazzarini/Shutterstock.com